FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3100253145> ?p ?o ?g. }

• W3100253145 abstract "Background Key biomarkers under investigation for the ability to predict response to monotherapy PD-1 inhibitors such as pembrolizumab include PD-L1, TMB, MSI, and T-cell–inflamed gene expression profile (GEP). The KEYNOTE-180 trial ( NCT02559687 ) was a single-arm phase 2 study of pembrolizumab as third-line or greater therapy in advanced/metastatic esophageal/gastroesophageal junction adenocarcinoma or squamous cell carcinoma (SCC). ORR was 9.9% and median DOR was NR at the primary analysis. We investigated the relationship in KEYNOTE-180 between response to pembrolizumab and T-cell–inflamed GEP or PD-L1 expression by histology. Methods Patients received pembrolizumab 200 mg Q3W for ≤2 years until disease progression, toxicity, or withdrawal. The end points for this analysis were ORR, DOR, and PFS per RECIST v1.1 by central review and OS in the SCC and adenocarcinoma populations by GEP (non-low [≥–1.540] or low [<–1.540]; cutoff prespecified) and PD-L1 (CPS ≥10 or <10). Tumor GEP was determined using the NanoString nCounter Analysis System. PD-L1 expression was characterized using PD-L1 IHC 22C3 pharmDx. Data cutoff date was July 30, 2018. Results Of 121 total patients, 118 had an evaluable GEP score and 121 had an evaluable PD-L1 CPS. Fifty-one patients (42.1%) had GEP non-low tumors, 58 (48.0%) had CPS ≥10 tumors, and 31 (25.6%) had GEP non-low /CPS ≥10 tumors; 63 patients (52.1%) had SCC and 58 (47.9%) had adenocarcinoma. ORR was 15.4% with GEP non-low and 13.5% with GEP low among patients with SCC and 12% and 0% among patients with adenocarcinoma, respectively (table 1). ORR was 20% with CPS ≥10 and 7.1% with CPS <10 among patients with SCC and 4.3% and 5.7%, respectively, among patients with adenocarcinoma (table 2). Median OS was slightly higher among patients with SCC in the GEP non-low subgroup and the CPS ≥10 subgroup versus GEP low and CPS <10 subgroups, respectively (tables 1, 2); this trend was reversed among patients with adenocarcinoma (tables 1, 2). Median PFS ranged from 1.9 to 2.1 across histology/biomarker subgroups. Median DOR was NR regardless of GEP or CPS status (tables 1, 2). Abstract 261 Table 1 Response by GEP status and histologyaAnalysis by biomarker status was not possible because of the small sample size. Abstract 261 Table 2 Response by PD-L1 status and histologyaAnalysis by biomarker status was not possible because of the small sample size. Conclusions In KEYNOTE-180, data in a small number of patients suggested that measures of inflammation, like PD-L1 and GEP, may enrich for responses to pembrolizumab. In SCC, some trends toward enrichment were observed for both biomarkers, although the trend was stronger for PD-L1 CPS ≥10. In adenocarcinoma, a trend was observed for GEP but not for PD-L1; the small number of responders is limiting, and further studies are needed to understand molecular correlates in adenocarcinoma. Acknowledgements Medical writing and/or editorial assistance was provided by Tim Peoples, MA, ELS, and Holly C. Cappelli, PhD, CMPP, of the ApotheCom pembrolizumab team (Yardley, PA, USA). This assistance was funded by Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Trial Registration ClinicalTrials. gov, NCT02559687 Ethics Approval The study and the protocol were approved by the institutional review board or ethics committee at each site. Consent All patients provided written informed consent to participate in the clinical trial." @default.
• W3100253145 created "2020-11-23" @default.
• W3100253145 creator A5000371599 @default.
• W3100253145 creator A5000699599 @default.
• W3100253145 creator A5007591581 @default.
• W3100253145 creator A5008013789 @default.
• W3100253145 creator A5011700088 @default.
• W3100253145 creator A5026459010 @default.
• W3100253145 creator A5034108220 @default.
• W3100253145 creator A5043091366 @default.
• W3100253145 creator A5050136275 @default.
• W3100253145 creator A5050417026 @default.
• W3100253145 creator A5058748738 @default.
• W3100253145 creator A5061867713 @default.
• W3100253145 creator A5064343766 @default.
• W3100253145 creator A5068848511 @default.
• W3100253145 creator A5071502431 @default.
• W3100253145 creator A5073459177 @default.
• W3100253145 creator A5082685387 @default.
• W3100253145 creator A5082832235 @default.
• W3100253145 creator A5085123244 @default.
• W3100253145 creator A5086593040 @default.
• W3100253145 creator A5090604653 @default.
• W3100253145 date "2020-11-01" @default.
• W3100253145 modified "2023-10-17" @default.
• W3100253145 title "261 Association of T-cell–inflamed gene expression profile and PD-L1 status with efficacy of pembrolizumab in patients with esophageal cancer from KEYNOTE-180" @default.
• W3100253145 doi "https://doi.org/10.1136/jitc-2020-sitc2020.0261" @default.
• W3100253145 hasPublicationYear "2020" @default.
• W3100253145 type Work @default.
• W3100253145 sameAs 3100253145 @default.
• W3100253145 citedByCount "1" @default.
• W3100253145 countsByYear W31002531452022 @default.
• W3100253145 crossrefType "journal-article" @default.
• W3100253145 hasAuthorship W3100253145A5000371599 @default.
• W3100253145 hasAuthorship W3100253145A5000699599 @default.
• W3100253145 hasAuthorship W3100253145A5007591581 @default.
• W3100253145 hasAuthorship W3100253145A5008013789 @default.
• W3100253145 hasAuthorship W3100253145A5011700088 @default.
• W3100253145 hasAuthorship W3100253145A5026459010 @default.
• W3100253145 hasAuthorship W3100253145A5034108220 @default.
• W3100253145 hasAuthorship W3100253145A5043091366 @default.
• W3100253145 hasAuthorship W3100253145A5050136275 @default.
• W3100253145 hasAuthorship W3100253145A5050417026 @default.
• W3100253145 hasAuthorship W3100253145A5058748738 @default.
• W3100253145 hasAuthorship W3100253145A5061867713 @default.
• W3100253145 hasAuthorship W3100253145A5064343766 @default.
• W3100253145 hasAuthorship W3100253145A5068848511 @default.
• W3100253145 hasAuthorship W3100253145A5071502431 @default.
• W3100253145 hasAuthorship W3100253145A5073459177 @default.
• W3100253145 hasAuthorship W3100253145A5082685387 @default.
• W3100253145 hasAuthorship W3100253145A5082832235 @default.
• W3100253145 hasAuthorship W3100253145A5085123244 @default.
• W3100253145 hasAuthorship W3100253145A5086593040 @default.
• W3100253145 hasAuthorship W3100253145A5090604653 @default.
• W3100253145 hasConcept C121608353 @default.
• W3100253145 hasConcept C126322002 @default.
• W3100253145 hasConcept C143998085 @default.
• W3100253145 hasConcept C2777701055 @default.
• W3100253145 hasConcept C2780057760 @default.
• W3100253145 hasConcept C2781182431 @default.
• W3100253145 hasConcept C71924100 @default.
• W3100253145 hasConcept C90924648 @default.
• W3100253145 hasConceptScore W3100253145C121608353 @default.
• W3100253145 hasConceptScore W3100253145C126322002 @default.
• W3100253145 hasConceptScore W3100253145C143998085 @default.
• W3100253145 hasConceptScore W3100253145C2777701055 @default.
• W3100253145 hasConceptScore W3100253145C2780057760 @default.
• W3100253145 hasConceptScore W3100253145C2781182431 @default.
• W3100253145 hasConceptScore W3100253145C71924100 @default.
• W3100253145 hasConceptScore W3100253145C90924648 @default.
• W3100253145 hasLocation W31002531451 @default.
• W3100253145 hasOpenAccess W3100253145 @default.
• W3100253145 hasPrimaryLocation W31002531451 @default.
• W3100253145 hasRelatedWork W10123795 @default.
• W3100253145 hasRelatedWork W18238637 @default.
• W3100253145 hasRelatedWork W18557826 @default.
• W3100253145 hasRelatedWork W20825895 @default.
• W3100253145 hasRelatedWork W20962042 @default.
• W3100253145 hasRelatedWork W20970363 @default.
• W3100253145 hasRelatedWork W2975164 @default.
• W3100253145 hasRelatedWork W7604317 @default.
• W3100253145 hasRelatedWork W8428010 @default.
• W3100253145 hasRelatedWork W964261 @default.
• W3100253145 isParatext "false" @default.
• W3100253145 isRetracted "false" @default.
• W3100253145 magId "3100253145" @default.
• W3100253145 workType "article" @default.